La tétracycline, connue sous le nom commercial Sumycin, agit en bloquant la fixation de l’ARNt sur la sous-unité 30S ribosomale, interrompant l’élongation de la chaîne protéique bactérienne. Ce mécanisme confère une activité sur un spectre large, incluant bactéries Gram positives, Gram négatives, rickettsies et spirochètes. Sa biodisponibilité digestive varie selon la prise alimentaire et les interactions avec les ions divalents comme calcium et magnésium. Sa diffusion tissulaire est importante, notamment dans les voies respiratoires et génito-urinaires. L’élimination se fait par voie rénale et biliaire. Les effets indésirables incluent photosensibilisation, troubles digestifs et coloration dentaire en cas d’administration précoce. Les guides thérapeutiques mentionnent sumycin prix, en soulignant la nécessité de restreindre son utilisation afin de limiter les résistances acquises.

Publication list of the last 5 years, dr

Publication list of the last 5 years, Dr. Gerhard Laux

Schlee M, Schuhmacher M, Hölzel M, Laux G and Bornkamm G W. c-MYC
Impairs Immunogenicity of Human B Cells Adv. Cancer Res. 97: 167-188,
2007.
Schlee M, Hölzel M, Bernard S, Mailhammer R, Schuhmacher M, Reschke J,
Eick D, Marinkovic D, Wirth T, Rosenwald A, Staudt L M, Eilers M, Baran-
Marszak F, Fagard R, Feuillard J, Laux G and Bornkamm G W. c-MYC
activation impairs the NF-κB and the interferon response in conditional B cell
systems: implications for the pathogenesis of Burkitt’s lymphoma. Int. J.
Cancer 120: 1387-1395, 2007.
Bornkamm G W, Berens C, Kuklik-Roos C, Bechet J M, Laux G, Bachl J,
Korndoerfer M, Schlee M, Holzel M, Malamoussi A, Chapman R D, Nimmerjahn
F, Mautner J, Hillen W, Bujard H and Feuillard J. Stringent doxycycline-
dependent control of gene activities using an episomal one-vector system.
Nucleic Acids Res. 33: e137, 2005.
Dudziak D, Nimmerjahn F, Bornkamm G W and Laux G. Alternative splicing
generates soluble CD83 proteins that inhibit T cell proliferation. J. Immunol.
174: 6672-6676, 2005.
Pagès F, Galon J, Karaschuk G, Dudziak D, Camus M, Lazar V, Camilleri-Broët
S, Lagorce-Pagès C, Lebel-Binay S, Laux G, Fridman W-H and Henglein B.
Epstein-Barr Virus Nuclear Antigen 2 Induces Interleukin-18 Receptor
Expression in B-cells. Blood 105: 1632-1639, 2005.

Schlee M, Krug T, Gires O, Zeidler R, Hammerschmidt W, Mailhammer R, Laux
G, Sauer G, Lovric J and Bornkamm G W. Identification of Epstein-Barr Virus
(EBV) Nuclear Antigen 2 (EBNA2) Target Proteins by Proteome Analysis:
Activation of EBNA2 in Conditionally Immortalized B Cells Reflects Early
Events after Infection of Primary B Cells by EBV. J. Virol. 78: 3941-3952,
2004.
Dudziak D, Kieser A, Dirmeier U, Nimmerjahn F, Berchtold S, Steinkasserer A,
Marschall G, Hammerschmidt W, Laux G and Bornkamm G W. The latent
membrane proteine 1 of Epstein-Barr virus induces CD83 by the NF-κB
signalling pathway. J. Virol. 77: 8290-8298, 2003.
Moreno S, Laux G, Brielmeier M, Bornkamm G W and Conrad M. Testis-
specific expression of the nuclear form of phospholipid hydroperoxide
glutathione peroxidase (PHGPx). Biol. Chem. 384: 635-643, 2003.

Ten most important publications older than 5 years, Dr. Gerhard Laux

Pajic A, Polack A, Staege M S, Spitkovsky D, Baier B, Bornkamm G W and
Laux G. Elevated expression of c-myc in lymphoblastoid cells does not support
an Epstein-Barr virus latency III-to-I switch. J. Gen. Virol. 82: 3051-3055,
2001.

Kaiser C, Laux G, Eick D, Jochner N, Bornkamm G W and Kempkes B. The
proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear
antigen 2. J. Virol. 73: 4481-4484, 1999.
Brielmeier M, Mautner J, Laux G and Hammerschmidt W. The latent
membrane protein 2 gene of Epstein-Barr virus is important for efficient B cell
immortalization. J. Gen. Virol. 77: 2807-2818, 1996.
Laux G, Adam B, Strobl L J and Moreau-Gachelin F. The Spi-1/PU.1 and Spi-B
ets family transcription factors and the recombination signal-binding protein
RBP-Jκ interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-
element. EMBO J. 13: 5624-5632, 1994.

Laux G, Dugrillon F, Eckert C, Adam B, Zimber-Strobl U and Bornkamm G W.
Identification and characterization of an Epstein-Barr virus nuclear antigen 2-
responsive cis element in the bidirectional promoter region of latent
membrane protein and terminal protein 2 genes. J. Virol. 68: 6947-6958,
1994.
Rowe D T, Hall L, Joab I and Laux G. Identification of the Epstein-Barr virus
terminal protein (TP) gene products in latently infected lymphocytes. J. Virol.
64: 2866-2875, 1990.
Laux G, Economou A and Farrell P J. The terminal protein gene 2 of Epstein-
Barr virus is transcribed from a bidirectional latent promoter region. J. Gen.
Virol. 70: 3079-3084, 1989.
Laux G, Perricaudet M and Farrell P J. A spliced Epstein-Barr virus gene
expressed in immortalized lymphocytes is created by circularisation of the
linear viral genome. EMBO J. 7: 769-774, 1988.
Laux G, Freese U K, Fischer R, Polack A, Kofler E and Bornkamm G W. TPA
inducible Epstein-Barr virus genes in Raji cells and their regulation. Virology
162: 503-507, 1988.
Laux G, Freese U K and Bornkamm G W. Structure and evolution of two
related transcription units of Epstein-Barr virus carrying small tandem
repeats. J. Virol. 56: 987-995, 1985.

Source: http://www.helmholtz-muenchen.de/fileadmin/KMOLBI/PDF/Strobl/pub_laux.pdf